OncoMatch/Clinical Trials/NCT04877522
Asciminib Roll-over Study
Is NCT04877522 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies multiple treatments for chronic myelogenous leukemia.
Treatment: Asciminib single agent · Imatinib · Nilotinib · Bosutinib · Dasatinib · Asciminib single agent pediatric formulation — This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Chronic Myeloid Leukemia
Biomarker criteria
Required: BCR fusion
PH+ CML or PH+ ALL
Required: ABL1 fusion
PH+ CML or PH+ ALL
Demographics
Prior therapy
Must have received: asciminib (asciminib) — currently receiving
currently receiving treatment with asciminib (single agent or in combination with imatinib, nilotinib or dasatinib)
Must have received: tyrosine kinase inhibitor (imatinib, nilotinib, bosutinib) — currently receiving
currently receiving treatment with ... imatinib, nilotinib or bosutinib alone
Cannot have received:
Participant has been discontinued from parent study treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Michigan Med University of Michigan · Ann Arbor, Michigan
- Memorial Sloan Kettering · New York, New York
- Oregon Health Sciences University · Portland, Oregon
- Texas Oncology · Dallas, Texas
- Uni Of TX MD Anderson Cancer Cntr · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04877522 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior disqualifies patients from enrollment.
Does this trial require BCR?
Yes, BCR fusion is a required biomarker for enrollment.
Does this trial require ABL1?
Yes, ABL1 fusion is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 100 years or younger and at least 7 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify